A related commentary highlights that this is the second treatment (after nivolumab) with an overall survival advantage over a previous standard of care. It highlights that tolerability and health related-quality of life will be important features for treatment selection should both nivolumab and cabozantinib be available, and that the optimum way to prioritise agents and treatment sequences based on overall survival for patients with clear-cell renal cell carcinoma requires clarification.
Cabozanitib is a MET, RET and VEGFR2 inhibitor licensed for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. and under investigation for use in various other cancers